Netflix had a 'good enough quarter,' but the way it's running its business leaves something to be desired, says Loup Ventures' Gene Munster.
Netflix had a"good enough quarter," but the way it's running its business leaves something to be desired, widely followed tech investor Gene Munster told CNBC on Tuesday.
"At $10 a month they would have to add 30 million [subscribers]," said Munster, founder of the venture capital firm Loup Ventures. Netflix CEO Reed Hastings said he isn't worried about the increasing competition. Last week, Disney announced its streaming service, Disney+, will be available starting Nov. 12 for $6.99 per month or $69 per year. Apple also plans a streaming service, Apple TV+, which is expected to launch this fall.
"Netflix will do well. I think they're going to have great market share in the U.S. and globally. I don't necessarily believe that that's a good stock," he explained.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Chinese scientists defend implanting human gene into monkeys' brainsA Chinese researcher who sparked improved cognitive function in monkeys by implanting human genes into their brains has defended his experiment, which has divided the scientific community.
Read more »
Contract Drug Manufacturer Catalent to Buy Paragon Bioservices in $1.2 Billion DealDrug manufacturer Catalent will buy Paragon Bioservices for $1.2 billion, helping it expand its gene-therapy capabilities
Read more »
Catalent to acquire Paragon Bioservices for $1.2 billion in cashCatalent Inc. said Monday it has agreed to acquire Paragon Bioservices Inc. for $1.2 billion in cash. Calent, a provider of delivery technologies for drugs, biologics and consumer health products, said it expects the deal to close in the second quarter. Privately held Paragon is a viral vector development and manufacturing partner for gene therapies. "Paragon brings specialized expertise in adeno-associated virus (AAV) vectors, the most commonly used delivery system for gene therapy, as well as unique capabilities in GMP plasmids and lentivirus vectors," Catalent said in a statement. Paragon is expected to generate more than $200 million in revenue in 2019 with nearly 90% of that sum already in signed contracts. The deal is expected to boost Catalent's adjusted net income per share in the second full fiscal year after closing. Catalent will finance the deal with the proceeds of a $650 million term loan and by issuing $650 million of convertible preferred stock to funds tied to Leonard Green and Partners LP. Shares were not yet active premarket, but have fallen 2.4% in the last 12 months, while the S&P 500 has gained 9.5%.
Read more »
NASA Twins Study results show how a year in space affects an astronaut’s DNABy comparing blood samples from twins, one in space and one earthbound, researchers found that an individual's gene expression can be altered dramatically after spending a year in space.
Read more »
Ford shakes up management in a move to retool business model to high-tech auto market
Read more »
Netflix investor isn't worried about Disney, Apple streaming services — Netflix is 'future of film'Netflix shouldn't be worried about streaming wars, Morris Mark, CEO of Mark Asset Management, said Tuesday ahead of the company's fiscal earnings.
Read more »
Morning Update: Who Doesn't Love A Good Cry In The MorningA record number of family apprehensions, the protests in Sudan, to catch a colleague. Your BuzzFeed News newsletter, April 10.
Read more »